ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2170-Liverpool-Liverpool-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
48
trial(s) found.
NCT07063745
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (
MountainTAP-29
)
PRMT5 inhibitor,MTA-co-operative
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06953960
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma (
2024-517140-65--M25-275
)
Bcl2 inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
NCT06898450
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair (
9216-101
)
WRN inhibitor
Cancer
Solid tumour
NSW
2170 - Liverpool - Liverpool Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06803680
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors (
BGB-B455-101
)
bispecific T-cell engager,CLDN6-targeting
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06796907
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors (
BEHOLD-2
)
anti-B7H4 antibody-drug conjugate
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
NCT06685718
Advanced
Phase 1
Recruiting
Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (
BG-60366-101
)
EGFR CDAC degrader
Cancer
Lung cancer
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06625593
Advanced
Phase 1
Recruiting
A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors (
BG-C137-101
)
anti-FGFR2b antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06618287
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors (
CA244-0001
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06578247
Haem
Phase 3
Recruiting
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (
QuANTUM-WILD
)
FLT3 inhibitor
KIT inhibitor
placebo
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06433219
Advanced
Phase 2
Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) (
MS201924-0002
)
ATM inhibitor
ATR inhibitor
PARP inhibitor
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06230224
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (
OLYMPIA-4
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06215118
Haem
Phase 1
Recruiting
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (
MagnetisMM-30--C1071030
)
CELMoD agent
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06198426
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI3004A101
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd (TERMINATED)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (TERMINATED)
2170 - Liverpool - Liverpool Hospital (TERMINATED)
NCT06170190
Advanced
Phase 1 / Phase 2
Recruiting
A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours (
CIBI133A101
)
anti-ERBB3 monoclonal antibody
Solid tumour
NSW
2170 - Liverpool - Liverpool Hospital
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
cancer therapy
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06127654
Radonc
Phase 3
Not yet recruiting
VITaL
: A Randomised Controlled Trial Investigating Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
radiotherapy
Lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Endometrial cancer
Lung adenocarcinoma
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05794906
Curative
Phase 3
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer (
ARASTEP
)
antiandrogen,nonsteroidal,second generation
placebo
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
2109 - North Ryde - Macquarie University Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (WITHDRAWN)
VIC
3002 - East Melbourne - Epworth Freemasons
3051 - Melbourne - Australian Prostate Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Tasman Oncology (WITHDRAWN)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (WITHDRAWN)
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)
2170 - Liverpool - Liverpool Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Townsville - Townsville University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (WITHDRAWN)
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05640999
Radonc
Phase 2
Recruiting
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER) (
EN10
)
Radiotherapy
cancer therapy
Endometrial cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05618028
Haem
Phase 1
Recruiting
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (
2022-503136-13--M23-324
)
MALT1 inhibitor
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital
NCT05514054
Curative
Phase 3
Recruiting
EMBER-4
: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
selective estrogen receptor degrader
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4215 - Southport - Gold Coast University Hospital
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05261399
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (
SAFFRON
).
EGFR inhibitor,third generation
MET inhibitor,type 1
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (WITHDRAWN)
QLD
4215 - Southport - Gold Coast University Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT04994717
Haem
Phase 3
Recruiting
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) (
2023-503640-14--20190360
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, =80 Years, or Frail =75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03666000
Haem
Phase 1
Recruiting
Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (azercabtagene Zapreleucel or "azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and R/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12625000484448
Radonc
Not Applicable
Not yet recruiting
Investigating the use of Stereotactic Ablative Body Radiation (SABR) Dose Escalation and Tri-Modality Treatment in Muscle-Invasive Bladder Cancer (MIBC) on local disease control outcomes. (
Bladder-Boost
)
Radiotherapy
cancer therapy
Bladder cancer
NSW
2170 - Liverpool - Liverpool Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACTRN12625000438459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (
ZEPFHR-MM-Domain-1
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12625000429459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (
ZEPFHR-MM
)
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621001548820
Radonc
Not Applicable
Not yet recruiting
A Phase 2 study investigating the feasibility of stereotactic ablative body radiotherapy for the palliation of Head and Neck Cancer (
STEREOPHONIC
)
radiotherapy
Head and neck cancer
NSW
2170 - Liverpool - Liverpool Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001458820
Haem
Phase 1
Not yet recruiting
Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (
CHARMM
)
anti-malarial agent
proteasome inhibitor
Cancer
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000586819
Radonc
Phase 2
Recruiting
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (
TROG-20.01-CHEST-RT
)
anti-PD-L1 monoclonal antibody
radiotherapy
topoisomerase inhibitor
Cancer
Lung cancer
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12621000418875
Radonc
Not Applicable
Recruiting
MAnTRA
: Mri-linAc Treatments for Radiotherapy Patients. A Pilot study on the use of the Australian MRI –Linac to Treat Cancer Radiotherapy Patients.
radiotherapy
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACTRN12620001198910
Radonc
Phase 2
Recruiting
Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (
MODERN-LUNG
)
Carboplatin
Durvalumab
Paclitaxel
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
taxane
Lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (44)
Not yet recruiting (4)
Recruitment Country and State
NSW (47)
VIC (34)
QLD (31)
WA (20)
SA (18)
NZ (8)
ACT (5)
TAS (5)
NT (2)
Phase
Phase 1 (10)
Phase 1 / Phase 2 (7)
Phase 2 (10)
Phase 2 / Phase 3 (1)
Phase 3 (17)
Trial Type
Advanced (19)
Haem (17)
Radonc (8)
Curative (4)
Cancer Therapy Class
PD-1/PD-L1
21%
PD-1
17%
cereblon
13%
EGFR
13%
proteasome
8%
PARP
8%
CD38
6%
GPRC5D
6%
CD20
6%
BCMA
6%
ERBB3
4%
XPO1
4%
ER
4%
oestrogen axis
4%
VEGF
4%
CD19
4%
PD-L1
4%
PRMT5
2%
Bcl2
2%
WRN
2%
CLDN6
2%
B7H4
2%
EGFR CDAC
2%
FGFR2
2%
FGFR2b
2%
FLT3
2%
KIT
2%
DNA methyltransferase
2%
IDH1
2%
IDH1 R132
2%
ATM
2%
ATR
2%
Trop2
2%
CS1
2%
ERBB2
2%
CDK4
2%
CDK6
2%
FR-alpha
2%
PARP1-selective
2%
AR
2%
androgen axis
2%
CD93
2%
gp100
2%
MALT1
2%
MET
2%
KRAS
2%
KRAS G12C
2%
CCR8
2%
CD79b
2%
LAG3
2%
CTLA4
2%
PI3K
2%
PI3K alpha
2%
PI3K delta
2%
mTOR
2%
mTORC1
2%
mTORC2
2%
Facility
2170 - Liverpool - Liverpool Hospital (48)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (17)
4102 - Woolloongabba - Princess Alexandra Hospital (16)
3168 - Clayton - Monash Medical Centre (16)
2050 - Camperdown - Chris O'Brien Lifehouse (14)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (14)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (12)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (11)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (11)
3000 - Melbourne - Peter MacCallum Cancer Centre (10)
3004 - Melbourne, Southbank - Alfred Health (9)
3128 - Box Hill - Box Hill Hospital - Eastern Health (9)
3066 - Epping - Northern Hospital (7)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (7)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (7)
6150 - Murdoch - Fiona Stanley Hospital (7)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (7)
3065 - Fitzroy - St Vincent's Hospital Melbourne (7)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (6)
2605 - Garran - The Canberra Hospital (5)
7000 - Hobart - Royal Hobart Hospital (5)
2500 - Wollongong - Wollongong Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
5042 - Bedford Park - Flinders Medical Centre (5)
4215 - Southport - Gold Coast University Hospital (5)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (5)
4575 - Birtinya - Sunshine Coast University Hospital (4)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (4)
2139 - Concord - Concord Repatriation General Hospital (4)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
2217 - Kogarah - St George Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (3)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
3002 - East Melbourne - Epworth Freemasons (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3630 - Shepparton - Goulburn Valley Health (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
4215 - Southport - Tasman Oncology (2)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (2)
2060 - North Sydney - Mater Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3051 - Melbourne - Australian Prostate Centre (1)
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (1)
NA
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4812 - Townsville - Townsville University Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Lung cancer
Respiratory tract cancer
Thoracic cancer
Multiple myeloma
Plasma cell disorder
Non-small cell lung cancer
Breast cancer
Lymphoma
Non-Hodgkin's lymphoma
Leukaemia
Gynaecological cancer
Ovarian cancer
Urogenital cancer
B-cell lymphoma
B-cell malignancy
Lymphoid leukaemia
Mature B-cell malignancy
Gastrointestinal cancer
Endometrial cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Colorectal cancer
Lower gastrointestinal cancer
Acute lymphoblastic leukaemia
Head and neck cancer
Upper gastrointestinal cancer
Myelodysplastic syndrome
Myeloproliferative neoplasm
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
Male genital cancers
Prostate cancer
Chronic lymphocytic leukaemia
Breast adenocarcinoma
Cervical cancer
Clear cell renal cell carcinoma
Colorectal adenocarcinoma
Exocrine pancreatic cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
HPV-related cancer
HPV16-positive cancer
Head and neck squamous cell carcinoma
Kidney cancer
Melanoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Oesophageal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
Urothelial carcinoma
Viral-related cancer
B-cell acute lymphoblastic leukaemia/lymphoma
Bladder cancer
EGFR-mutant non-small cell lung cancer
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy